How has Nuvalent, Inc.'s accrued expenses and other liabilities changed year-over-year?

Nuvalent, Inc.'s accrued expenses and other liabilities decreased by 471.8% year-over-year, from -$373K to -$2.13M.

Nuvalent, Inc. NUVL Accrued expenses and other liabilities

Revolution Medicines, Inc.RVMD

——

Vertex PharmaceuticalsVRTX

——

Operating income-$119.4M-25.9%

Net income-$109.3M-29.2%

EPS (diluted)-$1.39-17.8%

Cash & equivalents$159.7M+32.2%

Total equity$1.2B+16.2%

Total assets$1.3B+20.4%

Operating cash flow-$92.4M-68.5%

Market cap$9.77B+58.6%

Return on equity-41.2%+7.5pp

Current ratio16.1×+1.7×

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Nuvalent, Inc.'s accrued expenses and other liabilities?: Nuvalent, Inc. (NUVL) reported accrued expenses and other liabilities of -$2.13M in Q1 2026.
How has Nuvalent, Inc.'s accrued expenses and other liabilities changed year-over-year?: Nuvalent, Inc.'s accrued expenses and other liabilities decreased by 471.8% year-over-year, from -$373K to -$2.13M.